TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06241703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICCAUT
Description: For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Free drainage
Description: For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
Study: NCT05776979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given by vein over about 75 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given by PO
Study: NCT06441825

Intervention type: OTHER
Intervention: Increased multimodal observation including digital monitoring
Description: Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
Study: NCT06176820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Gel
Description: Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal lubricant
Description: Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
Study: NCT04734535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST™ Bellows
Description: Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable gelatin sponge with thrombin
Description: Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
Study: NCT05699785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma inflammatory markers
Description: Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma inflammatory markers
Description: Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Description: Evolution of CD4/CD8 ratio

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Description: Evolution of CD4/CD8 ratio
Study: NCT06249321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX plus IMRT
Description: Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
Study: NCT05761704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet
Description: Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel oral anticoagulant
Description: Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
Study: NCT04230668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy with Suicide Risk Management
Description: CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual with Suicide Rick Management
Description: In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
Study: NCT04823364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurotransmitters evaluation by MRS
Description: Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
Study: NCT04167683

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06172114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using sticky bone
Description: In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using sticky bone
Description: In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
Study: NCT06348264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
Study: NCT06360952

Intervention type: DEVICE
Intervention: Tasso+ CBC
Description: Novel blood collection device

Intervention type: DEVICE
Intervention: Tasso+ CBC
Description: Novel blood collection device

Intervention type: DEVICE
Intervention: Tasso+ CBC
Description: Novel blood collection device
Study: NCT06064045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-based team training intervention
Description: Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~1. Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~2. Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~3. Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~4. Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period).
Study: NCT05925062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QActual
Description: QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
Study: NCT05936918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical acupoint stimulatios
Description: Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulatios
Description: Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
Study: NCT04811664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine
Description: A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine
Description: A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
Study: NCT05988333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational Family Intervention
Description: Supportive intervention administered to families with a member affected by MDD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative intervention
Description: Informative intervention administered to families with a member affected by MDD
Study: NCT05461937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting things done after stroke
Description: A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke psychoeducation
Description: A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
Study: NCT05936918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral transverse abdominal plane block
Description: Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral transverse abdominal plane block
Description: Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
Study: NCT04658654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: chronic intervention (24 weeks): roflumilast capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: chronic intervention (24 weeks): roflumilast capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Pill with inactive ingredients to mimic same appearance of roflumilast capsule
Study: NCT05097209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent cisplatin
Description: Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study: NCT06339749

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
Study: NCT05732558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system
Description: The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
Study: NCT06339749

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).

Intervention type: OTHER
Intervention: Clinical protocols for preeclampsia risk screening
Description: In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester.

Intervention type: OTHER
Intervention: Clinical protocols for preeclampsia risk screening
Description: In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester.
Study: NCT05082207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: a deflated cuff placed on the upper arm for 30 min
Study: NCT04680637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Administered as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Administered as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Administered as a subcutaneous (SC) injection.
Study: NCT05855408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscularly administered Ad5-nCoV vaccine
Description: This vaccine is produced by CanSino Biologics Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV
Description: This vaccine is produced by CanSino Biologics Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DelNS1-2019-nCoV-RBD-OPT1
Description: This vaccine is produced by Wantai Biopharmaceutical Company.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6006
Description: This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
Study: NCT05052697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection
Study: NCT04680637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a subcutaneous (SC) injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
Study: NCT05981404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-glucan
Description: Consuming 3g β-glucan with each meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Consuming 3g Cellulose with each meal.
Study: NCT03280316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients with SVMs receive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients with SVMs receive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients with SVMs receive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral neuromodulation
Description: sacral neuromodulation (SNM) with InterStimTM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin A injection
Description: BOTOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M receptor antagonist
Description: Tolterodine
Study: NCT05368909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Supplement
Description: Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Supplement
Description: Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo product
Study: NCT05032729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trypophan, Theanine and 5'AMP
Description: 250 ml beverage consumed at 21:00 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trypophan, Theanine and 5'AMP
Description: 250 ml beverage consumed at 21:00 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
Study: NCT05345756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral protraction device
Description: Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraoral protraction device
Description: Facemask which is an extraoral appliance used for maxillary protraction
Study: NCT05286164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 150 mg QD for 8 weeks